Metabolic research
Retatrutide review
A selected obesity trial shows a weight-loss signal. That finding does not validate products sold outside clinical development.
Peptide Index is operated by the team behind Peptide Guide, a peptide vendor. Read our disclosure.
Included evidence
Human phase 2 trial
What was studied
Adults with obesity or overweight and a weight-related condition in a randomized placebo-controlled trial.
What the research found
- Participants assigned retatrutide lost more weight than those assigned placebo in the selected trial.
- Gastrointestinal effects and increased heart rate were reported.
Where the evidence stops
- This review covers the cited trial, not a complete account of the development program.
- Trial findings do not verify the contents or safety of an online vial.
Safety context
FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
Educational information only. This review does not recommend self-treatment or establish that products sold online match a studied formulation. Individual medical decisions belong with a qualified clinician.
Read the sources
These are the documents included in this review. Evidence labels describe this selection; they are not effectiveness or safety scores.
Original research — PubMed abstract
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (opens in a new tab)FDA safety information
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (opens in a new tab)
This is a selected-source editorial review, not a systematic review or a claim of medical review. New findings may change the assessment.
Next editorial check due .
How these reviews are prepared